THE ROLE OF HERPES VIRUS INFECTION IN CLINICAL MANIFESTATIONS AND SEVERITY OF EXPERIMENTAL RADIATION OROPHARYNGEAL SYNDROME
https://doi.org/10.25016/2541-7487-2013-0-4-70-75
Abstract
Experimental models of radiation oropharyngeal syndrome were developed for both isolated (radiation) and combined (radiation, chemical and herpes virus) exposure of laboratory animals. Preliminary infecting the tested animals with herpes simplex type 1 virus (HVS-1) before chemical and radiation exposure increased radiation lesions in mucous membrane of the oral cavity in rats, thus aggravating oral mucositis with about 40 % death rate. When Molixan, possessing immunomodulating and antivirus properties, was used for treatment and prevention, radiation oropharyngeal syndrome incidence decreased by 2-3 times, along with symptom severity, thus enabling all the tested animals to survive.
About the Authors
A. A. Antushevitch
Saint-Petersburg State Pediatric Medical University
Russian Federation
Antushevitch Anna Aleksandrovna - Ph, assistant of Stomatology Department
Russian Federation
Antushevitch Anna Aleksandrovna - Ph, assistant of Stomatology Department
A. E. Antushevitch
Kirov Military Medical Academy, Saint-Petersburg
Russian Federation
Antushevitch Alexander Evgenjevich - MD, Prof., senior scientist of Research Laboratory (military therapy), Research Center
Russian Federation
Antushevitch Alexander Evgenjevich - MD, Prof., senior scientist of Research Laboratory (military therapy), Research Center
A. N. Grebenyuk
Kirov Military Medical Academy, Saint-Petersburg
Russian Federation
Grebenyuk Alexander Nikolaevich - MD, Prof., Head Toxicologist-Radiologist of Defence Ministry of Russia, Head of Military Toxicology and Medical Protection
Russian Federation
Grebenyuk Alexander Nikolaevich - MD, Prof., Head Toxicologist-Radiologist of Defence Ministry of Russia, Head of Military Toxicology and Medical Protection
A. V. Stepanov
Kirov Military Medical Academy, Saint-Petersburg
Russian Federation
Stepanov Aleksandr Valentinovich - MD, Head of the Research test center (medico-biological defence) Department, Research probationary Institute of Military Medicine
Russian Federation
Stepanov Aleksandr Valentinovich - MD, Head of the Research test center (medico-biological defence) Department, Research probationary Institute of Military Medicine
V. G. Antonov
Kirov Military Medical Academy, Saint-Petersburg
Russian Federation
Antonov Victor Georgievich - MD, senior lecturer of Clinical Biochemistry and Laboratory Diagnosis Department
Russian Federation
Antonov Victor Georgievich - MD, senior lecturer of Clinical Biochemistry and Laboratory Diagnosis Department
A. G. Klimov
Saint-Petersburg State Pediatric Medical University
Russian Federation
Klimov Andrei Gennadievich - Ph, senior lecturer, Head of Stomatology Department
Russian Federation
Klimov Andrei Gennadievich - Ph, senior lecturer, Head of Stomatology Department
References
1. Kanaev S.V., Gershanovich M.L. Rol' preparata Tantum verde v profilaktike i lechenii porazhenii slizistoi obolochki polosti rta pri tsitostaticheskoi terapii i obluchenii u onkologicheskikh bol'nykh [The role of drug Tantum verde in the prevention and treatment of lesions of the oral mucosa with cytostatic therapy and irradiation in cancer patients]. Voprosy onkologii [Problems in oncology]. 2004. Vol. 50, N 5. Pp. 618–622. (In Russ.)
2. Butomo N.V. [et al.]. Osnovy meditsinskoi radiobiologii [Fundamentals of Medical Radiobiology]. Ed. I.B. Ushakov. Sankt-Peterburg. 2004. 384 p. (In Russ.)
3. Rebrova O.Yu. Statisticheskii analiz meditsinskikh dannykh: primenenie paketa prikladnykh programm Statistica [Statistical analysis of medical data: application of Statistica software package]. Moskva. 2002. 312 p. (In Russ.)
4. Avetisov G.M. [et al.]. Sindromy ostroi luchevoi bolezni. Klinicheskie proyavleniya, profilaktika i lechenie [Syndromes of acute radiation sickness. Clinical manifestations, prevention and treatment]. Moskva. 2003. 244 p. (In Russ.)
5. Radzhapova M.U. [et al.] Sravnitel'naya otsenka reaktsii slizistoi obolochki pri raznofraktsionnoi khimioluchevoi terapii raka polosti rta i rotoglotki [Comparative evaluation of mucosal reactions with multiple fraction chemoradiotherapy for cancer of the oral cavity and oropharynx]. Sibirskii onkologicheskii zhurnal [Siberian Journal of oncology]. 2011. N 1. Pp. 12–15. (In Russ.)
6. Jose G.G. [et al.]. A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo. Invest. Ophthalmol. Vis. Sci. 2013. Vol. 54, N 2. P. 1070–1079.
7. Kenney J. [et al.]. A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo. Antimicrob. Agents Chemother. 2013. Vol. 57, N 8. Pp. 4001–4009.
8. Braff M.H., Bardan A., Nizet V., Gallo R.L. Cutaneous defense mechanisms by antimicrobial peptides. J. Invest. Dermatol. 2005. Vol. 125. Pp. 9–13.
9. Leoni V. [et al.]. Herpes simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble gH/gL is sufficient to activate NF-kB. J. Virol. 2012. Vol. 86, N 12. Pp. 6555–6562.
10. Braff M.H. [et al.]. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect. Immun. 2005. Vol. 73. Pp. 6771–6781.
11. Lehrer R.I., Lichtenstein A.K., Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Ann. Rev. Immunol. 1993. Vol. 11. Pp. 105–128.
12. Trotti A. [et al.]. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systemic literature review. Radiother. Oncol. 2003. Vol. 66, N 3. Pp. 253–263.
13. Murrah V.A. Virus and oral cancer. Oral Oncology. 1995. Vol. 4. Pp. 231–235.
14. Galdiero S. [et al.]. Peptide inhibitors against herpes simplex virus infections. J. Pept. Sci. 2013. Vol.19, N 3. Pp. 148–158.
15. Schroder J.M., Harder J. Antimicrobial skin peptides and proteins. Cell. Mol. Life Sci. 2006. Vol. 63. Pp. 469–486.
16. Schroder J.M., Harder J. Human beta-defensin-2. Int. J. Biochem. Cell Biol. 1999. Vol. 31. Pp. 645–651
17. Sonis S.T. The pathobiology of mucositis. Nat. Rev. Cancer. 2004. Vol. 4, N 4. Pp. 277–284.
18. Stewart M.W. Herpetic (non-cytomegalovirus) retinal infections in patients with the acquired immunodeficiency syndrome. Curr. HIV Res. 2013. Vol. 11, N 3. Pp. 210–219.
19. Langendijk J.A. [et al.]. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J. Clin. Oncol. 2004. Vol. 22. Pp. 4604–4612.
20. Villa A., Treister N.S. Intraoral herpes simplex virus infection in a patient with common variable immunodeficiency. Oral Surg. Med. Pathol. Radiol. 2013. Vol. 116, N 4. Pp. 277–279.
Review
For citations:
Antushevitch A.A., Antushevitch A.E., Grebenyuk A.N., Stepanov A.V., Antonov V.G., Klimov A.G. THE ROLE OF HERPES VIRUS INFECTION IN CLINICAL MANIFESTATIONS AND SEVERITY OF EXPERIMENTAL RADIATION OROPHARYNGEAL SYNDROME. Medicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations. 2013;(4):70-75. (In Russ.) https://doi.org/10.25016/2541-7487-2013-0-4-70-75
Views:
446
Email this article 